Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$158.56 USD
-2.08 (-1.29%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $158.55 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JNJ 158.56 -2.08(-1.29%)
Will JNJ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Time for Healthcare ETFs?
Other News for JNJ
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
IN BRIEF: J&J subsidiary's Rybrevant recommended for further approval
AbbVie: Growth Is Still A Better Choice
Video: Dow Movers: JNJ, MCD
Stocks Going Ex Dividend In August 2024